ID25548A - Senyawa-senyawa heterosiklik spiroazabisiklik terbaru - Google Patents

Senyawa-senyawa heterosiklik spiroazabisiklik terbaru

Info

Publication number
ID25548A
ID25548A IDW20000024A ID20000024A ID25548A ID 25548 A ID25548 A ID 25548A ID W20000024 A IDW20000024 A ID W20000024A ID 20000024 A ID20000024 A ID 20000024A ID 25548 A ID25548 A ID 25548A
Authority
ID
Indonesia
Prior art keywords
spiroazabiciclic
heterosiclic
latest
compounds
spiroazabiciclic heterosiclic
Prior art date
Application number
IDW20000024A
Other languages
English (en)
Indonesian (id)
Inventor
Eifion Phillips
Robert Mack
John Macor
Simon Semus
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702746A external-priority patent/SE9702746D0/xx
Priority claimed from SE9800977A external-priority patent/SE9800977D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of ID25548A publication Critical patent/ID25548A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW20000024A 1997-07-18 1998-07-10 Senyawa-senyawa heterosiklik spiroazabisiklik terbaru ID25548A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702746A SE9702746D0 (sv) 1997-07-18 1997-07-18 New compounds
SE9800977A SE9800977D0 (sv) 1998-03-24 1998-03-24 New compounds

Publications (1)

Publication Number Publication Date
ID25548A true ID25548A (id) 2000-10-12

Family

ID=26663041

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000024A ID25548A (id) 1997-07-18 1998-07-10 Senyawa-senyawa heterosiklik spiroazabisiklik terbaru

Country Status (31)

Country Link
US (6) US6110914A (et)
EP (2) EP0996622B1 (et)
JP (1) JP2001510194A (et)
KR (1) KR100560036B1 (et)
CN (1) CN1117755C (et)
AR (2) AR013184A1 (et)
AT (2) ATE283859T1 (et)
AU (1) AU739022B2 (et)
BR (1) BR9810924A (et)
CA (1) CA2296031C (et)
DE (2) DE69827977T2 (et)
DK (1) DK0996622T3 (et)
EE (1) EE04399B1 (et)
ES (2) ES2185185T3 (et)
HK (3) HK1025322A1 (et)
HU (1) HUP0003844A3 (et)
ID (1) ID25548A (et)
IL (2) IL134086A0 (et)
IS (2) IS2027B (et)
MY (1) MY116761A (et)
NO (1) NO325324B1 (et)
NZ (1) NZ502298A (et)
PL (1) PL193065B1 (et)
PT (1) PT996622E (et)
RU (1) RU2202553C2 (et)
SA (1) SA98190668B1 (et)
SI (1) SI0996622T1 (et)
SK (1) SK283484B6 (et)
TR (1) TR200000129T2 (et)
TW (1) TW515799B (et)
WO (1) WO1999003859A1 (et)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA984637B (en) 1997-05-30 1998-12-21 Neurosearch As Spiro-quinuclidine derivatives their preparation and use
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
SI1397366T1 (sl) * 2001-06-01 2007-06-30 Astrazeneca Ab Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
NZ554913A (en) * 2001-12-14 2009-01-31 Targacept Inc Methods and compositions for the treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
DE60334536D1 (de) * 2002-04-18 2010-11-25 Astrazeneca Ab Furylverbindungen
NZ535978A (en) * 2002-04-18 2007-10-26 Astrazeneca Ab Novel spiroazabicyclic heterocyclic amines useful as nicotinic acetylcholine receptor agonists
NZ561993A (en) * 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP4750421B2 (ja) † 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN100355756C (zh) * 2003-01-08 2007-12-19 三菱制药株式会社 精神分裂症的治疗剂
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
BRPI0414633A (pt) 2003-09-25 2006-11-07 Astrazeneca Ab composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit
DK1678172T3 (da) 2003-10-15 2010-04-06 Targacept Inc Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
CA2543436A1 (en) * 2003-10-21 2005-05-12 Astrazeneca Ab Spirofuropyridine aryl derivatives
EP1734941A2 (en) * 2004-03-25 2006-12-27 The Feinstein Institute for Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2006073484A2 (en) 2004-12-27 2006-07-13 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
JP2009506037A (ja) 2005-08-22 2009-02-12 ターガセプト，インコーポレイテッド ヘテロアリール置換ジアザトリシクロアルカン、その調製方法およびその使用方法
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20080242688A1 (en) * 2007-03-19 2008-10-02 Astrazeneca Ab Method 741
CN103977003A (zh) 2007-04-02 2014-08-13 帕金森氏病研究院 用于降低治疗的副作用的方法和组合物
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
CN101883771A (zh) 2007-10-01 2010-11-10 科门蒂斯公司 作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
EP2254598B1 (en) 2008-02-13 2013-07-10 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
EA201001889A1 (ru) 2008-06-20 2011-08-30 Астразенека Аб Производные дибензотиазепина и их применение
CN102215909B (zh) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
RS56812B1 (sr) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-hloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidrohlorid monohidrata
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
RU2455306C1 (ru) * 2011-05-19 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ]
KR20140027939A (ko) 2011-06-30 2014-03-07 도레이 카부시키가이샤 지양제
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
US8893339B2 (en) 2013-03-14 2014-11-25 Select Comfort Corporation System and method for adjusting settings of a bed with a remote control
AU2014282977B2 (en) 2013-06-21 2018-06-14 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017524736A (ja) 2014-07-11 2017-08-31 アルファーマゲン，エルエルシー アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
EP3405107B1 (en) 2016-01-20 2023-04-12 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited DRUG DELIVERY METHODS AND SYSTEMS
EP3856180A1 (en) 2018-09-24 2021-08-04 Astrazeneca AB Azd0328 dosage regime for treating cognitive impairment
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
WO2021236977A1 (en) 2020-05-21 2021-11-25 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
CN115340736B (zh) * 2022-05-20 2023-09-29 扬州实嘉电缆材料有限公司 一种氮磷阻燃剂改性聚氯乙烯防火电缆料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681363A (en) * 1970-08-20 1972-08-01 Univ Temple Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
JP4176147B2 (ja) * 1995-07-28 2008-11-05 アボツト・ラボラトリーズ 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Also Published As

Publication number Publication date
NZ502298A (en) 2002-02-01
DK0996622T3 (da) 2002-12-30
NO20000226L (no) 2000-03-14
PL338259A1 (en) 2000-10-09
DE69827977D1 (de) 2005-01-05
US7507744B2 (en) 2009-03-24
EP1213291A1 (en) 2002-06-12
WO1999003859A1 (en) 1999-01-28
IL134086A0 (en) 2001-04-30
ATE225792T1 (de) 2002-10-15
BR9810924A (pt) 2000-08-15
NO325324B1 (no) 2008-03-31
TW515799B (en) 2003-01-01
US6706878B2 (en) 2004-03-16
HK1025322A1 (en) 2000-11-10
HK1046274B (zh) 2005-05-20
US20030166935A1 (en) 2003-09-04
PL193065B1 (pl) 2007-01-31
AR068013A2 (es) 2009-10-28
IS2027B (is) 2005-08-15
US6369224B1 (en) 2002-04-09
IL134086A (en) 2007-08-19
TR200000129T2 (tr) 2000-07-21
IS2434B (is) 2008-10-15
IS5338A (is) 2000-01-13
EE04399B1 (et) 2004-12-15
AU8367998A (en) 1999-02-10
HUP0003844A3 (en) 2002-11-28
JP2001510194A (ja) 2001-07-31
ES2185185T3 (es) 2003-04-16
HUP0003844A2 (hu) 2001-07-30
HK1031382A1 (en) 2001-06-15
EP1213291B1 (en) 2004-12-01
NO20000226D0 (no) 2000-01-17
CA2296031C (en) 2008-01-08
AU739022B2 (en) 2001-10-04
KR100560036B1 (ko) 2006-03-13
HK1046274A1 (en) 2003-01-03
US6703502B2 (en) 2004-03-09
DE69808631T2 (de) 2003-06-12
KR20010021961A (et) 2001-03-15
DE69808631D1 (de) 2002-11-14
EP0996622A1 (en) 2000-05-03
PT996622E (pt) 2003-01-31
US6110914A (en) 2000-08-29
ATE283859T1 (de) 2004-12-15
CA2296031A1 (en) 1999-01-28
AR013184A1 (es) 2000-12-13
ES2231599T3 (es) 2005-05-16
SA98190668B1 (ar) 2006-09-25
CN1270592A (zh) 2000-10-18
SK183599A3 (en) 2000-08-14
EP0996622B1 (en) 2002-10-09
DE69827977T2 (de) 2005-12-08
MY116761A (en) 2004-03-31
SK283484B6 (sk) 2003-08-05
SI0996622T1 (en) 2003-04-30
RU2202553C2 (ru) 2003-04-20
US20020187994A1 (en) 2002-12-12
CN1117755C (zh) 2003-08-13
EE200000031A (et) 2000-10-16
IS7747A (is) 2005-03-16
US20080153864A1 (en) 2008-06-26
US20050004099A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
ID25548A (id) Senyawa-senyawa heterosiklik spiroazabisiklik terbaru
PT860428E (pt) Compostos pirimidiona
IS5479A (is) Efnasambönd
IS5478A (is) Efnasambönd
IS5477A (is) Efnasambönd
ID22850A (id) Senyawa-senyawa pirazina
IS5354A (is) Ný efnasambönd
LTC1124961I2 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
NO994877D0 (no) Kalsilytiske forbindelser
ID28266A (id) Senyawa-senyawa amidin
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
ID27004A (id) Senyawa-senyawa kalsilitik
EE9900448A (et) Ühendid
NO20006662L (no) Fluorfenylresin-forbindelser
IS5237A (is) Efnasambönd
IS5323A (is) Efnasambönd
ID22983A (id) Senyawa-senyawa fluorometoksimino
NO995007D0 (no) Forbindelser
ID17393A (id) Aril-piridazina terbaru
DE59804807D1 (de) Pi-komplex-verbindungen
DE69737634D1 (de) Insektizide oxadiazinverbindungen
ITRM970524A3 (it) Il toglisinghiozzo
ID19442A (id) Senyawa terbaru
SE9701964D0 (sv) Compounds